Oncology

Latest News

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Community Oncology Reacts to Trump's Drug Pricing Executive Order

By Maggie L. Shaw

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com

Patient Navigation Is Nonnegotiable in Cancer Care

By Maggie L. Shaw

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 29th 2016

Need to Revisit Cervical Cancer Screening Guidelines: JAMA Oncology Study

Surabhi Dangi-Garimella, PhD

A new study has found that after adjusting for changes in screening, there was a decrease in incidence of all grades of cervical intraepithelial neoplasia (CIN) for women 15- to 19-years old, and CIN grade 2 in women 20- to 24-years old.

September 28th 2016

USPSTF Recommendation Did Not Impact PSA Testing Referrals, Study Finds

Surabhi Dangi-Garimella, PhD

A study published in the journal Cancer has discovered that a 2012 recommendation for prostate cancer screening did not change physician behavior.

Dr Ally-Khan Somani: Mohs Surgery Is a Gold Standard

September 28th 2016

Dr Ally-Khan Somani: Mohs Surgery Is a Gold Standard

Mohs surgery is generally the gold standard for rare and more aggressive tumors because the surgeon can ensure the roots of the tumor are gone, but the technique keeps the hole small, said Ally-Khan B. Somani, MD, PhD, at the 25th European Academy of Dermatology and Venereology Congress.

Dr Aleksandar Krunic Discusses the Reimbursement Issues of Mohs Surgery

September 28th 2016

Dr Aleksandar Krunic Discusses the Reimbursement Issues of Mohs Surgery

Reimbursement issues surrounding Mohs surgery are getting worse, which provides a challenge for surgeons who would perform the procedure, explained Aleksandar L. Krunic, MD, PhD, during the 25th European Academy of Dermatology and Venereology Congress.

September 28th 2016

Chemotherapy and RT Improve Survival in Surgically Resected Medulloblastoma Patients

Surabhi Dangi-Garimella, PhD

A new study presented at the annual meeting of the American Society for Radiation Oncology has found a significant survival advantage of combining chemotherapy and radiotherapy following surgery in patients with medulloblastoma.

September 27th 2016

SBRT Improves Outcomes in Older NSCLC Patients With Stage I Disease

Surabhi Dangi-Garimella, PhD

Use of stereotactic body radiation therapy improved survival in elderly patients diagnosed with early-stage non-small cell lung cancer by about 20% over a decade.

September 27th 2016

The Big "C" — Is Cancer Curable?

Advancement in basic science and medical technology has made cancer a curable disease for many patients. Approximately 40% of Americans will be diagnosed with cancer in their lifetime, but as of 2014, 1 in 22 Americans is a cancer survivor, which equals 14.5 million cancer survivors in the US, explained Joseph C. Alvarnas, MD, director of value-based analytics for the City of Hope.

September 27th 2016

The Patient Lens on Precision Medicine

Jack Whelan, an e-patient advocate and patient with a rare blood disease, spoke at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. In his presentation, Whelan explained that patient centricity and education is important for all parties in the healthcare industry to better take hold of.

September 27th 2016

How Do Patients Define Value in Cancer Care?

In the United States healthcare system, discussions of value are almost always associated with the equation of quality over cost. However, patients don’t necessarily think that way, explained Yousuf Zafar, MD, MHS, associate professor of medicine and public policy at the Duke Cancer Institute.

September 27th 2016

Oncology and the President's Precision Medicine Initiative

While President Barack Obama outlined a series of budget plans for oncology care in the fall of 2015, which was designed to allocate an estimated $130 million to sequence 1 million volunteers, $70 million to identify “genome drivers” and $10 million to the FDA to build databases, Michael A. Kolodziej, MD, FACP, national medical director of Oncology Solutions at Aetna, believes there to be different areas of oncology care that need more attention and resources. Kolodziej presented at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Meeting.

September 27th 2016

Updates in Big Data for Oncology: What Are We Learning?

There are a number of issues concerning big data in the oncology world, the most prominent of which concerns the number of patients participating in clinical trials, Robert J. Green, MD, MSCE, vice president of clinical strategy at Flatiron Health, explained during his presentation at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Meeting. He added that only 4% of adult cancer patients participate in a clinical trial.

September 27th 2016

Outcomes from Mandatory Genetic Testing and Counseling Programs

Family history is at the core of precision medicine, Joy Larsen Haidle, MS, CGC, 2015 president of the National Society of Genetic Counselors, said during her presentation at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. During her presentation, Haidle explained that while hereditary cancer was traditionally viewed as occurring between 5% and 10% of the cancer population, recent data suggest that number may be a lot closer to 25% today.

September 27th 2016

The Impacts of FDA Regulations on Diagnostics in Oncology

Scott Gottlieb, MD, resident fellow at the American Enterprise Institute; Michael A. Kolodziej, MD, national medical director of oncology strategy at Aetna; Bruce Quinn, MD, PhD, MBA, senior director at FaegreBD Consulting; and Joy Larsen Haidle, MS, CGC, 2015 president of the National Society of Genetic Counselors, discussed the impacts of FDA regulation on diagnostics in oncology during The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. The panel discussion was moderated by Dennis P. Scanlon, professor of health policy and administrator and director of the Center for Health Care and Policy Research at The Pennsylvania State University.

September 27th 2016

Reimbursement Challenges for Oncology Innovations: Who Pays?

Competition as a means of tackling the escalating issue of drug prices is not working, said Peter B. Bach, MD, MAPP, physician at Memorial Sloan Kettering Cancer Center, in a panel discussion at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. He explained that implementing a system in which the attributes of the drug determine its price is a more reasonable, value-based approach.

September 27th 2016

Using Our Collective Wisdom to Thrive in a Post-SGR World

One of the reasons Julie M. Vose, MD, MBA, FASCO, 2015-2016 president of the American Society of Clinical Oncology, became involved with medicine in the first place was the ability to help patients. However, she said that the administrative burden physicians take on in today’s health system can often take away from that experience.

Navigating the Conflict of Personalized Medicine vs Population Management

September 27th 2016

Navigating the Conflict of Personalized Medicine vs Population Management

Population health is a method that looks at the total costs of care, focuses on the prevalent chronic diseases, and, additionally, examines the various social determinants of health of an entire community. However, Burton F. VanderLaan, MD, FACP, medical director of Priority Health, explained that precision medicine, specifically in precision oncology, seeks to do just the opposite by employing variation and individualizing treatment rather than standardizing it.

The Role of PBMs in Managing High-Cost Treatment Options

September 27th 2016

The Role of PBMs in Managing High-Cost Treatment Options

Stacey W. McCullough, DO, senior vice president of Pharmacy at Tennessee Oncology, PLLC; Bruce W. Sherman, MD, FCCP, FACOEM, medical director for Population Health Management for the RightOpt private exchange offering for Buck Consultants, A Xerox Company; and Glen D. Stettin, MD, senior vice president of clinical research and new solutions at Express Scripts, came together to discuss the role of pharmacy benefit managers (PBMs) as a means of helping to manage high-cost treatment options. The discussion, moderated by Bruce A. Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, was held during The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting.

Evolution of the ACO Model to Meet the Needs of Oncology Patients and Payers

September 27th 2016

Evolution of the ACO Model to Meet the Needs of Oncology Patients and Payers

Julian Malinak, MPH, finance lead for the pioneer accountable care organization (ACO) and next generation ACO models and technical advisor for financial policy at CMS Innovation Center, explained that CMS, as well as other organizations, are pushing away from the traditional fee-for-service methods by creating delivery models like ACOs and employing various tools and services, such as bundled payments, and are beginning to examine these methods in the oncology setting.

Evaluation of Options and Outcomes in a "Me Too" Market

September 27th 2016

Evaluation of Options and Outcomes in a "Me Too" Market

In the past 5 years, the FDA has approved 52 new agents for oncology use, and 24 of those agents have novel mechanisms, explained Stacey W. McCullough, PharmD, senior vice president of Pharmacy at Tennessee Oncology, PLLC, during her presentation at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. With these emerging options in oncology care, there are 3 things to consider when choosing the appropriate option for the patient, she said.

September 26th 2016

A New Biomarker Predicts Response to Pembrolizumab in Advanced Melanoma

Surabhi Dangi-Garimella, PhD

A new study by researchers at the Perelman School of Medicine has identified a predictive biomarker in stage IV patients with melanoma being treated with the pembrolizumab.

September 23rd 2016

UnitedHealth's 2017 Formulary to Support Generic and Biosimilar Drugs

Surabhi Dangi-Garimella, PhD

UnitedHealth has posted a presentation on its website that provides an update to its pharmacy benefits and prescription drug lists for 2017.

September 22nd 2016

Cancer Prevention Possible Through Lifestyle Control, Says JAMA Oncology Study

Surabhi Dangi-Garimella, PhD

Research published in the journal JAMA Oncology argues that major lifestyle changes can significantly delay the onset of cancer.

September 22nd 2016

Carolina Breast Cancer Study Reinforces Relation Between Racial Disparity and QOL

Surabhi Dangi-Garimella, PhD

Research conducted at the University of North Carolina Lineberger Comprehensive Cancer Center has found that white women performed better than black women on physical and functional health-related quality-of-life (HRQOL) scores, but not spiritual HRQOL.

September 20th 2016

Colombia Takes a Stand on Price of Novartis' Leukemia Drug

Surabhi Dangi-Garimella, PhD

Colombia has decided to slash the price of imatinib mesylate (Gleevec), manufactured by Novartis, by nearly half.

September 20th 2016

Improved Design, Access, and Transparency of Trials Essential for Success of Cancer Moonshot

Surabhi Dangi-Garimella, PhD

The National Cancer Institute's Cancer Moonshot initiative received yet another boost following Vice President Joe Biden’s announcement of several activities to accelerate the pace of oncology clinical research.

September 19th 2016

Managing Neutropenia in Patients With Soft Tissue Sarcomas

Using prophylaxis with biosimilar granulocyte colony-stimulating factor can reduce the severity of neutropenia in patients with soft tissue sarcoma.

This Week in Managed Care: September 17, 2016

September 17th 2016

This Week in Managed Care: September 17, 2016

This week, the top managed care stories included news that Risa Lavizzo-Mourey, MD, MBA, will be leaving the Robert Wood Johnson Foundation, a report that obesity rate in the military are also on the rise, and CMS denied Ohio's proposal to charge fees for Medicaid.

September 16th 2016

ASCO President Dr Daniel F. Hayes Applauds Recommendations for Cancer Moonshot

Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care reached out to Daniel F. Hayes, MD, FASCO, 2016-2017 president of the American Society of Clinical Oncology (ASCO), to understand his perception of how the recommendations of the Cancer Moonshot initiative's Blue Ribbon Panel would impact cancer care in the United States.

September 16th 2016

Obesity: A Growing Burden for Cancer Survivors

Patients with a history of cancer were more likely to suffer from obesity than the general population. This incidence was even greater in patients who were survivors of colorectal and breast cancers.

September 16th 2016

NCHS Report: Rising Survivorship in Pediatric Cancers, Brain Cancer Leading Cause of Death

Surabhi Dangi-Garimella, PhD

There has been a steady decline in death rates among children and adolescent patients diagnosed with cancer (ages 1 to 19 years), minus gender or racial disparity, between 1999 and 2014, according to a new report from the National Center for Health Statistics.

...

90 91 92 93 94 95 96 97 98

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions